Evidence map›Paper›PMID 36540473›Full record

ArticleCureus2022

Rapidly Progressive Bilateral Vitreoretinal Lymphoma.

Joseph W Fong, Riley N Sanders, David L Baker, Sergio Pina-Oviedo, Sami Uwaydat

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Joseph W FongDepartment of Ophthalmology, University of Tennessee Health Science Center - Hamilton Eye Institute, Memphis, USA.
Riley N SandersDepartment of Ophthalmology, University of Arkansas for Medical Sciences, Little Rock, USA.
David L BakerDepartment of Ophthalmology, Baker Eye Institute, Conway, USA.
Sergio Pina-OviedoDepartment of Pathology, Duke University Hospital, Durham, USA.
Sami UwaydatDepartment of Ophthalmology, University of Arkansas for Medical Sciences, Little Rock, USA.
Duke University Hospital · USUniversity of Arkansas for Medical Sciences · USBaker Engineering (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 56-year-old male who presented with unilateral localized sub-retinal lesions suspicious for primary vitreoretinal lymphoma (PVRL) developed florid bilateral ocular involvement and was found to have lesions on MRI of the brain in a five-week period despite the absence of vitreous involvement during the entire course of his disease. His ocular lesions were monitored while on systemic treatment and an excellent clinical response was achieved. His central nervous system (CNS) lesions, however, continued to progress despite chemotherapy and whole-brain radiation. He died 12 months from his time of ocular diagnosis. To our knowledge, this case represents the most rapid progression of PVRL reported in the literature - from unilateral, localized lesions in the sub-retinal space to bilateral ocular involvement and identification of CNS involvement in a five-week period. This case highlights the potential for rapid ocular progression of PVRL stressing the need for early diagnosis. Therefore, we recommend prompt vitreous and, if necessary, sub-retinal biopsy in cases of suspected vitreoretinal lymphoma in addition to neuro-imaging. We emphasize the importance of coordination between pathologists, ophthalmologists, and oncologists for prompt, accurate diagnosis. Delay in diagnosis and treatment can result in rapid intraocular progression and central nervous system spread.

Indexed as

central nervous system lymphomaocular lymphomaprimary vitreoretinal lymphomarapid progression lymphomavitreoretinal surgery

Identifiers

PMID36540473
PMCPMC9757659
OpenAlexW4309493249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.